<DOC>
	<DOCNO>NCT02576561</DOCNO>
	<brief_summary>The purpose research study test safety effectiveness investigational study vaccine , call TVGV-1 . The study test vaccine woman high grade HPV cervical infection .</brief_summary>
	<brief_title>Safety Efficacy Study TVGV-1 Vaccine Treat HPV Induced Cervical HSIL</brief_title>
	<detailed_description>The purpose Phase 2a Study VAX 02-01 assess safety activity TVGV-1 vaccine construct achieve absence histologic HSIL ( CIN2/3 ) ( regression LSIL le ) assess biopsy last study Visit 11 , Day 270 . The objective TVGV-1 program develop non-surgical alternative reliable , safe , would avoid potential surgical risk preterm birth , perinatal mortality , risk infertility , incontinence disfigurement , well reduce cost inconvenience otherwise economically productive young subject population .</detailed_description>
	<mesh_term>Squamous Intraepithelial Lesions Cervix</mesh_term>
	<criteria>1 . Female age 18 55 year 2 . Written inform consent accordance institutional guideline 3 . Negative pregnancy test ( urine blood test ) 4 . Women child bear potential must agree use contraception one menstrual cycle post end study early withdrawal , would visit 11 . Methods include intrauterine device double barrier method , hormonal contraceptive combination double barrier method . 5 . Patients ONLY HPV 16 OR HPV 16 AND 18 HighRisk HPV Cobas test include . 6 . Histologically confirm , positive HSIL CIN2+ high ( CIN2+/3 subject select ) cervical biopsy , confirm external ( independent ) pathologist panel within 12 week prior enrollment . If standard care biopsy available evaluation independent pathologist , fresh biopsy endocervical curettage require . The extent colposcopic HSIL disease involve two quadrant cervix . Biopsies take affected quadrant 7 . Adequate visualization entire cervix , cervical lesion ( ) squamouscolumnar junction 8 . Normal electrocardiogram ( ECG ) , laboratory value ( chemistry , complete blood count ) urinalysis , judge Grade 01 per National Cancer Institute Common Toxicity Criteria ( NCICTC ) 9 . Agrees Loop Electrosurgical Excision Procedure ( LEEP ) , Cold Knife Conization ( CKC ) Hysterectomy perform end study accord standardofcare 1 . History cancer ( exclude basal cell carcinoma skin ) include cervical cancer 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 ( See Appendix G ) 3 . Administration blood product within 3 month enrollment 4 . Active infection require antimicrobial treatment would interfere interpretation adverse event , cutaneous reaction efficacy . Treatment minor concurrent infection limit less 10 day . 5 . Administration vaccine within 8 week enrollment within 4 week flu vaccine . 6 . Participation study investigational compound device within 30 day prior sign inform consent 7 . Any hematologic disorder involve platelet clot abnormality condition require treatment transfusion , anticoagulant except platelet inhibitor ( NSAIDs need pain permit ) 8 . Active drug alcohol use dependence , opinion Site Investigator , would interfere adherence study protocol 9 . Skin condition require consistent use topical corticosteroid local systemic therapy may interfere interpretation description skinrelated adverse event link vaccination 10 . The standard criterion prospective clinical trial medication develop DrugInduced Liver Injury Network ( establish The National Institute Diabetes Digestive Kidney Diseases ) use assess laboratory test abnormality . Normal range lab typically 5 40 IU/L AST ; 7 56 IU/L ALT ; 0.2 1.2 mg/dL bilirubin . Subjects exclude value x 2x 2.5 upper limit 11 . Evidence hematopoietic , cardiovascular , hepatic , renal , neurologic , psychiatric , dermatologic , immune disorder , disease may interfere assessment safety efficacy vaccine activity indicate study objective 12 . Any known allergic reaction vaccine component 13 . Any medical condition ( ) , judgment Site Investigator , might interfere study require treatment might interfere study 14 . Family member investigation study staff 15 . Pregnant breastfeed 16 . Inability provide inform consent 17 . A subject history expectation noncompliance medication treatment protocol 18 . Receipt ( e.g . Gardasil® Cervarix® ) HPV preventative vaccine within 8 year study enrollment 19 . Excessive use acetaminophen potentially hepatotoxic drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>human papillomavirus</keyword>
	<keyword>Cervical Intraepithelial Neoplasia</keyword>
	<keyword>Cold Knife Conization</keyword>
	<keyword>hysterectomy</keyword>
	<keyword>Loop Electrosurgical Excision Procedure</keyword>
	<keyword>LEEP</keyword>
	<keyword>HSIL</keyword>
	<keyword>High-Grade Squamous Intraepithelial Lesion</keyword>
</DOC>